BioXcel Therapeutics (BTAI) Profit After Tax (2017 - 2026)

BioXcel Therapeutics' Profit After Tax history runs 10 years deep, the most recent figure standing at -$12.7 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 74.95% year-over-year to -$12.7 million in Q1 2026; TTM through Mar 2026 was -$75.3 million, a 88.04% decrease from a year earlier, with the FY2025 full-year figure at -$69.9 million, down 17.28% from the prior year.
• Profit After Tax fell to -$12.7 million in Q1 2026 per BTAI's latest filing, from -$12.5 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$7.3 million in Q1 2025 and bottomed at -$54.8 million in Q4 2022.
• The 5-year median for Profit After Tax is -$26.8 million (2024), against an average of -$28.6 million.
• Across the five-year window, Profit After Tax soared 84.49% in 2024 and tumbled 131.2% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$54.8 million in 2022, then soared by 59.39% to -$22.3 million in 2023, then surged by 51.21% to -$10.9 million in 2024, then dropped by 15.53% to -$12.5 million in 2025, then retreated by 1.16% to -$12.7 million in 2026.
• Per Business Quant, the three latest BTAI Profit After Tax figures stand at -$12.7 million (Q1 2026), -$12.5 million (Q4 2025), and -$30.9 million (Q3 2025).